From the Maastricht University Medical Center , University Eye Clinic Maastricht, Maastricht, the Netherlands (Spekreijse, Bauer, van den Biggelaar, Simons, Veldhuizen, Berendschot, Nuijts); School for Mental Health and Neuroscience (MHeNs), Maastricht University, Maastricht, the Netherlands (Spekreijse, Simons, Veldhuizen).
J Cataract Refract Surg. 2022 May 1;48(5):542-548. doi: 10.1097/j.jcrs.0000000000000791. Epub 2021 Aug 19.
To evaluate refractive outcomes for the Clareon monofocal intraocular lens (IOL) in terms of achieved target refraction for the ORA (ALCON) intraoperative wavefront aberrometry device and preoperative noncontact biometry.
University Eye Clinic Maastricht, Maastricht University Medical Center+, the Netherlands.
Prospective observational clinical trial.
Patients with bilateral age-related cataracts undergoing phacoemulsification, either by delayed sequential surgery or on the same day, were included in the study. Exclusion criteria were an increased risk for refractive surprise or complicated surgery. Implanted IOL power was based on noncontact optical biometry data using the Barrett Universal II (BU-II) formula, optimized for the Clareon IOL. Postoperative subjective refraction was measured 4 to 6 weeks after surgery. Catquest-9SF questionnaires were completed preoperatively and 3 months after surgery.
100 eyes (51 patients) were included. The percentages of eyes within 1.0 diopters (D), 0.75 D, 0.50 D, and 0.25 D of target for ORA vs BU-II were 84% (84 eyes), 72% (72 eyes), 57% (57 eyes), and 21% (21 eyes) vs 97% (97 eyes), 88% (88 eyes), 77% (77 eyes), and 53% (53 eyes), respectively. Mean absolute prediction error was significantly higher for ORA vs preoperative biometry (P < .001). After global optimization, the prediction accuracy of ORA improved significantly (P < .001). Catquest-9SF questionnaires showed improved levels of ability at 3 months after surgery (P < .001).
This study showed lower percentages of eyes within target refraction for ORA (prior to lens constant optimization) compared with the BU-II formula when implanting the Clareon IOL. However, prediction accuracy of ORA improved significantly after global optimization. Therefore, further intraoperative measurements, postoperative measurements, and optimization are needed to improve the ORA prediction for this IOL.
使用 ORA（ALCON）术中波前像差仪和术前非接触式生物测量仪评估 Clareon 单焦点人工晶状体（IOL）的屈光结果，以达到目标屈光度。
荷兰马斯特里赫特大学眼科诊所，马斯特里赫特大学医学中心+。
前瞻性观察性临床试验。
患有年龄相关性白内障的双侧患者接受超声乳化白内障吸除术，要么是通过延迟序贯手术，要么是同一天进行。排除标准为屈光意外风险增加或手术复杂。植入 IOL 度数基于非接触式光学生物测量数据，使用 Barrett Universal II（BU-II）公式，针对 Clareon IOL 进行优化。术后 4 至 6 周测量术后主观屈光度。术前和术后 3 个月完成 Catquest-9SF 问卷。
100 只眼（51 例）入选。ORA 与 BU-II 的目标范围内 1.0 屈光度（D）、0.75 D、0.50 D 和 0.25 D 的眼比例分别为 84%（84 眼）、72%（72 眼）、57%（57 眼）和 21%（21 眼），而 97%（97 眼）、88%（88 眼）、77%（77 眼）和 53%（53 眼）。ORA 与术前生物测量的平均绝对预测误差明显更高（P <.001）。经过全局优化，ORA 的预测准确性显著提高（P <.001）。Catquest-9SF 问卷显示术后 3 个月的能力水平有所提高（P <.001）。
这项研究表明，在植入 Clareon IOL 时，与 BU-II 公式相比，ORA 的目标屈光度范围内的眼比例较低。然而，经过全局优化，ORA 的预测准确性显著提高。因此，需要进一步进行术中测量、术后测量和优化，以提高这种 IOL 的 ORA 预测准确性。
